Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

November 25, 2022

Study Completion Date

December 31, 2022

Conditions

Male InfertilityHCV

Interventions

DRUG

Sofosbuvir +daclatasvir+ simeprevir+Ribavirin

Oral daily dose of Sofosbuvir +daclatasvir + simeprevir+ Ribavirin for 3 months

Trial Locations (2)

Faculty of Medicine, Benha University, Al Qalyūbīyah

Benha Faculty of Medecine, Banhā

All Listed Sponsors

lead

Benha University

OTHER